A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase II Study of Subcutaneously Administered Interferon Beta 1a in the Treatment of Patiens with Aktive Rheumatoid Arthritis

Abstract

Subcutaneously Administered Interferon Beta 1, Aktive Rheumatoid Arthritis